| |
| |
|
| Insider
Information: |
Sharp John P |
| Relationship: |
Chief Financial Officer |
| City: |
San Diego |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
3 |
|
| Direct
Shares |
86,653 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$1,234,747 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
86,653 |
|
|
| Total
Value |
$1,234,747 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Sequenom Inc |
SQNM |
Treasurer |
2007-01-18 |
3,219 |
2007-01-18 |
0 |
Premium* |
|
|
Ligand Pharmaceuticals Inc |
LGND |
VP Finance and CFO |
2014-02-12 |
17,667 |
2007-06-20 |
0 |
Premium* |
|
|
Phasebio Pharmaceuticals Inc |
PHAS |
Chief Financial Officer |
2022-05-20 |
65,767 |
2018-12-07 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| PHAS |
Phasebio Pharmaceuticals ... |
Chief Financial Officer |
• – – |
2022-05-20 |
4 |
A |
$0.68 |
$4,106 |
D/D |
6,026 |
65,767 |
0 |
- |
|
| PHAS |
Phasebio Pharmaceuticals ... |
Chief Financial Officer |
• – – |
2021-11-19 |
4 |
A |
$2.01 |
$4,054 |
D/D |
2,017 |
59,741 |
0 |
- |
|
| PHAS |
Phasebio Pharmaceuticals ... |
Chief Financial Officer |
• – – |
2021-11-03 |
4 |
OE |
$1.68 |
$12,600 |
D/D |
7,500 |
57,724 |
0 |
- |
|
| PHAS |
Phasebio Pharmaceuticals ... |
Chief Financial Officer |
• – – |
2021-08-03 |
4/A |
OE |
$1.68 |
$12,600 |
D/D |
7,500 |
50,224 |
0 |
- |
|
| PHAS |
Phasebio Pharmaceuticals ... |
Chief Financial Officer |
• – – |
2021-08-03 |
4 |
A |
$1.68 |
$12,600 |
D/D |
7,500 |
50,224 |
0 |
- |
|
| PHAS |
Phasebio Pharmaceuticals ... |
Chief Financial Officer |
• – – |
2021-05-20 |
4 |
A |
$2.80 |
$3,973 |
D/D |
1,419 |
42,724 |
0 |
- |
|
| PHAS |
Phasebio Pharmaceuticals ... |
Chief Financial Officer |
• – – |
2020-11-20 |
4 |
A |
$3.00 |
$3,915 |
D/D |
1,305 |
41,305 |
0 |
- |
|
| PHAS |
Phasebio Pharmaceuticals ... |
Chief Financial Officer |
• – – |
2020-08-14 |
4 |
OE |
$1.69 |
$8,450 |
D/D |
5,000 |
40,000 |
0 |
- |
|
| PHAS |
Phasebio Pharmaceuticals ... |
CFO and Secretary |
• – – |
2019-08-21 |
4 |
OE |
$1.44 |
$24,100 |
D/D |
15,000 |
35,000 |
0 |
- |
|
| PHAS |
Phasebio Pharmaceuticals ... |
CFO and Secretary |
• – – |
2019-05-22 |
4 |
OE |
$1.69 |
$25,350 |
D/D |
15,000 |
20,000 |
0 |
- |
|
| PHAS |
Phasebio Pharmaceuticals ... |
CFO and Secretary |
• – – |
2018-12-07 |
4 |
B |
$3.84 |
$19,200 |
D/D |
5,000 |
5,000 |
2.74 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
VP Finance and CFO |
• – – |
2014-02-12 |
4 |
S |
$74.27 |
$6,498,898 |
D/D |
(86,953) |
17,667 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
VP Finance and CFO |
• – – |
2014-02-12 |
4 |
OE |
$9.96 |
$1,528,059 |
D/D |
86,953 |
25,162 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
VP Finance and CFO |
• – – |
2013-12-12 |
4 |
S |
$53.44 |
$37,408 |
D/D |
(700) |
17,667 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
VP Finance and CFO |
• – – |
2013-12-12 |
4 |
OE |
$9.96 |
$6,972 |
D/D |
700 |
18,367 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
VP Finance and CFO |
• – – |
2013-12-06 |
4 |
S |
$56.08 |
$336,480 |
D/D |
(6,000) |
17,667 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
VP Finance and CFO |
• – – |
2013-11-18 |
4 |
S |
$53.00 |
$59,519 |
D/D |
(1,123) |
23,667 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
VP Finance and CFO |
• – – |
2013-11-18 |
4 |
OE |
$9.96 |
$6,215 |
D/D |
624 |
24,790 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
VP Finance and CFO |
• – – |
2013-08-16 |
4 |
S |
$42.75 |
$320,619 |
D/D |
(7,500) |
24,166 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
VP Finance and CFO |
• – – |
2013-08-16 |
4 |
OE |
$9.96 |
$74,700 |
D/D |
7,500 |
31,666 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
VP Finance and CFO |
• – – |
2013-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
24,166 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
VP Finance and CFO |
• – – |
2011-02-17 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
16,666 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
VP Finance and CFO |
• – – |
2010-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
18,000 |
82,000 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
VP Finance and CFO |
• – – |
2009-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
64,000 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
VP Finance and CFO |
• – – |
2009-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
18,000 |
58,000 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
